EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study

Yilin Wang, Shida Pan, Jiahe Tian, Jianing Wang, Yingying Yu, Siyu Wang, Fengyi Li, Luo Yang, Xiaomeng Liu, Yingjuan Shen, Qin Qiu, Junqing Luan und 5 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04038-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yilin Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, No. 28, Fuxing Road, Beijing, 100853, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Programmed Cell Death 1 Receptor, CTLA-4 Antigen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changzhou Xi Taihu Cutting-edge Cell Therapy Technology Development Foundation, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study retrospectively evaluated the safety and efficacy of cadonilimab combined with tyrosine kinase inhibitors (TKI) for the treatment of unresectable hepatocellular carcinoma (uHCC). PATIENTS AND METHODS: Seventy-eight patients who received cadonilimab + TKI were included; 42 and 36 received it as first-line (1 L) and second-line and above (≥ 2 L) systemic treatment, respectively. Besides, ninety-five patients who received PD-1 inhibitor + TKI as first-line treatments were included. Safety was the primary endpoint; secondary endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). RESULTS: Treatment-related adverse events (TRAEs) of any grade occurred in 84.6% of the patients, with grade ≥ 3 in 20.5%. In patients with a Child-Pugh score of ≥ 8 (CP ≥ 8), any grade TRAEs occurred in 88.2%, and grade ≥ 3 in 20.6%. The overall cohort's median progression-free survival (mPFS) was 3.6 months, whereas the median overall survival (mOS) was 8.8 months. In the 1 L group, mPFS was 6.7 months versus 2.3 months in ≥ 2 L. In the 1 L group, mOS was 13.7 months versus 3.2 months in ≥ 2 L. For CP < 8, 1 L mPFS was 7.6 months, mOS not reached; CP ≥ 8 had mPFS of 5.2 months, mOS of 5.6 months. For CP < 8 in ≥ 2 L, mPFS was 3.1 months, mOS 8.8 months; CP ≥ 8 had mPFS of 1.4 months, mOS of 2.2 months. After propensity score matching (PSM), the incidence of TRAEs of any grade was 77.1%, with grade ≥ 3 accounting for 17.1% in the PD-1 group. In the PD-1/CTLA-4 group, the incidence of TRAEs of any grade was 80.0%, and that of grade ≥ 3 TRAEs was 17.1%. The mPFS was 6.7 months in the PD-1/CTLA-4 group versus 3.3 months in the PD-1 group. The mOS was 13.7 months in the PD-1/CTLA-4 group versus 6.7 months in the PD-1 group. CONCLUSION: Cadonilimab + TKI showed a favorable trend in safety and efficacy, especially when applied as first-line systemic therapy for uHCC. This study offers a clinical reference for its use in systemic uHCC therapy, particularly in patients with advanced liver dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsProgrammed Cell Death 1 ReceptorCTLA-4 AntigenAntibodies, BispecificHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Bispecific antibodyCadonilimabReal-world dataUnresectable hepatocellular carcinoma

Substanzen

Programmed Cell Death 1 ReceptorPDCD1 protein, humanCTLA-4 AntigenAntibodies, BispecificCTLA4 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical School of Chinese PLA, No. 28, Fuxing Road, Beijing, 100853, China.
  • Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing, 100853, China.
  • Capital Medical University, Beijing, 100069, China.
  • Peking University 302 Clinical Medical School, Beijing, 100191, China.
  • The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
  • Medical School of Chinese PLA, No. 28, Fuxing Road, Beijing, 100853, China. fswang302@163.com.

Förderung

  • Changzhou Xi Taihu Cutting-edge Cell Therapy Technology Development Foundation
  • National Key Research and Development Program of China

Zitieren

APA

Wang, Y., Pan, S., Tian, J., Wang, J., Yu, Y., Wang, S., Li, F., Yang, L., Liu, X., Shen, Y., Qiu, Q., Luan, J., Jia, M., Xiong, C., Duan, X., Wang, F. S., & Meng, F. (2025). Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04038-8

Vancouver

Wang Y, Pan S, Tian J, Wang J, Yu Y, Wang S, et al. Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04038-8

BibTeX
@article{Wang2025,
  author = {Wang, Yilin and Pan, Shida and Tian, Jiahe and Wang, Jianing and Yu, Yingying and Wang, Siyu and Li, Fengyi and Yang, Luo and Liu, Xiaomeng and Shen, Yingjuan and Qiu, Qin and Luan, Junqing and Jia, Mengdie and Xiong, Chuyue and Duan, Xuanxuan and Wang, Fu-Sheng and Meng, Fanping},
  title = {Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04038-8}
}
Kostenlos starten →